Immune Therapeutics, Inc. (IMUN)
OTC
Healthcare
Biotechnology
$0.09
▼ -7.00%
Market Cap
$7.8M
Sector
Healthcare
Industry
Biotechnology
Beta
0.26
52-Wk Range
0.06675-1.3
CEO
Noreen M. Griffin
Country
US
Currency
USD
Immune Therapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Winter Park, FL, US. The stock last traded at $0.09, down 7.00% on the session, giving a market capitalisation of $7.8M. On trailing twelve-month figures it carries a trailing P/E of -0.00, a net margin of 0.0%. Its beta of 0.26 implies it has historically moved less than the broad market.
Valuation & profitability (TTM)
P/E
-0.00
Price / Sales
0.00
Price / Book
-0.00
EV / EBITDA
-0.52
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Return on equity
—
Debt / equity
-0.25
Current ratio
0.01
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
—
IPO date
2010-08-20
Headquarters
Winter Park, FL, US
About Immune Therapeutics, Inc.
Immune Therapeutics, Inc. currently conducts no significant business operations. Formerly known as TNI BioTech, Inc., the company adopted its present name in October 2014. Its corporate headquarters are situated in Orlando, Florida.
Comparable companies
Immune Therapeutics, Inc. is most often compared with the following Healthcare names:
More research on IMUN
Open full interactive analysis & DCF →